Tally Zingher is the CEO of Dawsat, a Palestinian platform that supports thousands of people across the Arab world on their journey to wellness, combining digital tools, the latest in science and nutrition, and a passion for Arabic culture and food. Prior to co-founding Dawsat, Tally was Managing Director at Blue Laurel and the co-founding managing director of the MENA Investment Network. With expertise in Middle East economic development, Zingher is a term member of the Council on Foreign Relations.

Francois Maisonrouge has 31 years of experience advising companies in the Healthcare industry. As a Sr. Mangaging Director at Evercore Francois has advised on many transactions including advising Takeda on its acquisition of Ariad, Medivation on its sale to Pfizer, AstraZeneca on the sale of its anti-infectives business to Pfizer, just to name a few

Assaf Bash has led the Edwards Life Sciences (Israel) organization since 2010 and is responsible for new product development. He has tremendous experience in medical device development. Edwards is a global leader in patient-focused medical innovations for structural heart disease, critical care and surgical monitoring

Ofer Gonen is the CEO of Clal Biotechnology (CBI). Ofer has deep experience across biotechnology and serves on the boards of several healthcare companies.  He gained his experience in R&D through the prestigious TALPIOT program of the Israeli Defense Forces, for which he was awarded the Israeli National Security Medal.

Bill Doyle is an experienced healthcare executive whose experiences include working at Pershing Square Capital management, running several divisions at Johnson & Johnson, and is currently on the board of startup Blink Health, just to name a few of his accomplishments.

Dekel Gelman is CEO of DNA, whose technology is used by 70% of the world’s geneticists in over 130 countries. FDNA’s next-generation phenotyping (NGP) technologies analyze complex human physiological data to produce actionable genomic insights.

Genesis - aims to decrease the prevalence of genetic diseases among the 21M Bedouins in the Middle East through premarital genetic testing and matching.

Genesis offers a number of internships for students who wish to gain experience in the fields of public and global health, medical genetics, business development and market research, marketing and/or technological solutions for preventive medicine. Following are some of potential areas of responsibility:

1. Writing content – Conducting literature reviews on the common genetic diseases in the Bedouin community. End goal is both publishing scientific papers as well as establishing a web page that can be easily understood by all.

2. Global market research – Researching and mapping similar societies and solutions, to better understand the global problem. This will include gathering and analyzing external information about relevant issues, program design and operating environment, to allow us to make improved decisions on how to achieve our goals.

3. Cost-analysis reports – Writing cost-analysis reports on the common genetic diseases in the Bedouin community, based on the WHO guidelines.

4. Cost reduction analysis – Assisting in determining which costs our organization can cut without impacting its ability to deliver on its mission. Analyzing our administrative and operational expenses, workflows, and supply chain.

Additional ways in which you can make an impact: : evaluation and key performance indicators, pitch development (business proposal/grant writing), research grants & proposals, varied funding model, management reporting systems/databases organizational learning and knowledge management, HR policy manual, and social media/website.

Weekly schedule is flexible and work is done remotely. Several Harvard programs provide funding and credit opportunities which can be applied to these internships.

Early Sense has raised +$100mm to revolutionize patient monitoring through a contact-free health monitor for clinical and consumer markets.

Research Opportunities with Early Sense

Over the past 18 months, EarlySense has seen accelerated growth as it has started offering its sensing and analytics platform in a SAS like model to medical institutions. The company has tripled its installed base since the beginning of 2018, is now installing a new medical site every 3 days, and will monitor its 1,000,000th patient before the year ends.

Based on its recent success, EarlySense is looking to expand its offering in 2 possible ways as it builds itself to be IPO ready by the end of 2019:

1. Partner with other (likely smaller) companies that provide synergistic offerings into its customer base, to allow the EarlySense sales force to have a wider offering and leverage the existing and growing customer network to generate more revenues per customer

2. Offer clinical benchmarking and expert services in addition to the current products to its customers in order to generate additional revenues per customer (hospitals and post acute sites) and help customers achieve better clinical and economic outcomes

Early Sense be happy to have a team of students work on one or both of these challenges. Please contact: Hadar Ritte, EarlySense VP HR

Cukierman & Co. has raised and invested +$1bn globally. The company is supported by Chinese, French, and Israeli partners. Led by Edouard Cukierman, founder of Catalyst Funds and chairman of Cukierman and Co. Investment House through a contact-free health monitor for clinical and consumer markets.